Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 301–400 of 1,020
Hippisley-Cox, J., & Coupland, C. (2016) · BMJ · doi:10.1136/bmj.i3477 · Cited by 117
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Therapeutic Advances in Diabetic Nephropathy
Sawaf, H., Thomas, G., Taliercio, J. J., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020378 · Cited by 130
“Trials such as SAVOR-TIMI 53 [73] and CARMELINA [74] showed a possible reduction in albuminuria in patients receiving DPP-4 inhibitors.”
MethodSitagliptin Use in Patients With Diabetes and Heart Failure
Weir, D. L., McAlister, F. A., Senthilselvan, A., Minhas‐Sandhu, J. K., & Eurich, D. T. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.005 · Cited by 127
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Thrasher, J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 112
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 128
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
New insights into insulin action and resistance in the vasculature
Manrique, C. M., Lastra, G., & Sowers, J. R. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12395 · Cited by 132
The pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
“18) DPP-4 inhibitors Saxagliptin [122] Trial: N = 1 RCT Design: 5 mg Saxagliptin vs.”
BackgroundLee, M. M. Y., McMurray, J. J. V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. A., Jhund, P. S., & Petrie, M. C. (2018) · Heart · doi:10.1136/heartjnl-2016-310342 · Cited by 131
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Lapuerta, P., Zambrowicz, B., Strumph, P., & Sands, A. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114563304 · Cited by 119
Kim, S. C., Schneeweiß, S., Glynn, R. J., Doherty, M., Goldfine, A. B., & Solomon, D. H. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205216 · Cited by 126
Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
Scilletta, S., Marco, M. D., Miano, N., Filippello, A., Mauro, S. D., Scamporrino, A., Musmeci, M., Coppolino, G., Barbagallo, F. D. G., Bosco, G., et al. (2023) · Biomolecules · doi:10.3390/biom13050752 · Cited by 140
“In the SAVOR-TIMI 53 trial [76], type 2 diabetes patients with either a history of established CV disease or multiple risk factors for CV disease randomly received saxagliptin or a placebo.”
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1006625 · Cited by 126
“As in the SAVOR-TIMI 53 [15] and the EXAMINE [16] trials, they are comparing a DPP-4 inhibitor with placebo (sitagliptin in TECOS, linagliptin in CARMELINA) [88], except in the CAROLINA trial where linagliptin is compared with glimepiride, a sulfonylurea as active comparator [89].”
BackgroundMethodResultInfluentialSinha, B., & Ghosal, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.014 · Cited by 113
O’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113
Filion, K. B., Lix, L. M., Yu, O. H., Dell’Aniello, S., Douros, A., Shah, B. R., St-Jean, A., Fisher, A., Tremblay, E., Bugden, S. C., et al. (2020) · BMJ · doi:10.1136/bmj.m3342 · Cited by 117
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 121
“However, over the years it has been found that some of the anti-diabetic drugs, such as Liraglutide [121, 122] and saxagliptin [123, 124] increase the risk for heart failure.”
BackgroundScirica, B. M., Mosenzon, O., Bhatt, D. L., Udell, J., Steg, P. G., McGuire, D. K., Im, K., Kanevsky, E., Stahre, C., Sjöstrand, M., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4228 · Cited by 116
Self-citationTkáč, I., & Raz, I. (2017) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 112
Self-citationDo we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 121
“For example, the early suggestions that dipeptidyl peptidase 4 (DPP-4) inhibitors had protective cardiovascular effects have not been confirmed in large-scale clinical trials, with one reporting an increased incidence of hospitalization for heart failure in the DPP-4-treated arm [87].”
BackgroundDoyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111
Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., & Kothny, W. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12548 · Cited by 107
Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Meneses, M. J., Silva, B. M., Sousa, M., Sá, R., Oliveira, P. F., & Alves, M. G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710145753 · Cited by 132
“492 patients with T2DM showed that although DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events but the rate of hospitalization for heart failure was increased [234].”
BackgroundSharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Self-citationGantz, I., Chen, M., Suryawanshi, S., Ntabadde, C., Shah, S., O’Neill, E. A., Engel, S. S., Kaufman, K. D., & Lai, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0593-8 · Cited by 108
“5 years median follow-up of this study due to its early termination is shorter than that of the completed CV safety studies with similar designs and patient populations for the DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53) [6] and sitagliptin (TECOS) [4], which had median follow-ups of 2.”
ResultPenna, C. R. R., Andreadou, I., Aragno, M., Beauloye, C., Bertrand, L., Lazou, A., Falcão‐Pires, I., Bell, R., Zuurbier, C. J., Pagliaro, P., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14993 · Cited by 114
“…risks and benefits after administration of DPP-4 inhibitors have shown that hospitalisation for HF was increased in saxagliptin-treated patients (Scirica et al., 2013), whereas the rates of major adverse cardiovascular events were not increased with the alogliptin and sitagliptin as compared…”
Onódi, Z., Visnovitz, T., Kiss, B., Hambalkó, S., Koncz, A., Ágg, B., Váradi, B., Tóth, V. É., Nagy, R. N., Gergely, T. G., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.12.007 · Cited by 119
Treatment of type 2 diabetes mellitus in the elderly
Yakaryılmaz, F. D., & Öztürk, Z. A. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.278 · Cited by 140
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 127
“Indeed, the SAVOR-TIMI 53 trial reported that diabetic individuals without known CVD but with elevated NT-proBNP levels have a 3-fold increased risk of HF than counterparts with known CVD and normal NT-proBNP levels [78].”
BackgroundSitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-013-0169-1 · Cited by 117
“[continuation phase of SIT 100 od [106] -0.”
BackgroundRizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107
Fadini, G. P., Avogaro, A., Esposti, L. D., Russo, P., Saragoni, S., Buda, S., Rosano, G. M. C., Pecorelli, S., & Pani, L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv301 · Cited by 111
“1 years.(4) A subsequent re-analysis of this study reported that excess .”
BackgroundResultPaneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 127
“007).(53) However, these findings were not paralleled by a concomitant increase in HF-related deaths in patients taking saxagliptin (44 and 40 cases in saxagliptin and placebo, respectively).”
ResultPharmacological Treatment and Current Management of Peripheral Artery Disease
Bonaca, M. P., & Creager, M. A. (2015) · Circulation Research · doi:10.1161/circresaha.114.303505 · Cited by 113
Raparelli, V., Elharram, M., Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., & Pilote, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012940 · Cited by 106
Scheen, A. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 106
“1 years of follow-up, risk for pancreatitis in T2DM patients treated with saxagliptin was low and apparently similar to placebo, with no sign of increased risk for pancreatic cancer [132,133].”
BackgroundMethodDiabetes, hypertension, and chronic kidney disease progression: role of DPP4
Nistala, R., & Savin, V. J. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00316.2016 · Cited by 110
Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Hiroi, S., Onishi, Y., Guelfucci, F., & Shimasaki, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025806 · Cited by 104
Ou, S.-M., Shih, C.-J., Chao, P.-W., Chu, H., Kuo, S.-C., Lee, Y.-J., Wang, S.-J., Yang, C.-Y., Lin, C.-C., Chen, T.-J., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0308 · Cited by 101
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 108
D’Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E. M., & Patorno, E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6664 · Cited by 116
Xie, Y., Bowe, B., Xian, H., Loux, T., McGill, J. B., & Al-Aly, Z. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00171-7 · Cited by 104
Scirica, B. M., Bhatt, D. L., Braunwald, E., Raz, I., Cavender, M. A., Im, K., Mosenzon, O., Udell, J. A., Hirshberg, B., Pollack, P. S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3030 · Cited by 103
Self-citationScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“However, hard renal end points were similar in the saxagliptin group and placebo group, possibly because of a too short follow-up period [68].”
BackgroundHeart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
Self-citationGiugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012356 · Cited by 99
Pasternak, B., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1186 · Cited by 113
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 116
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
“60 ) P ub lis he d in fo rm at io n [8 ]”
BackgroundResultMulvihill, E. E., Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W. A., Abdullah, T., Baggio, L. L., & Drucker, D. J. (2016) · Diabetes · doi:10.2337/db15-1224 · Cited by 101
Lawson, C. A., Seidu, S., Zaccardi, F., McCann, G., Kadam, U. T., Davies, M. J., Lam, C. S., Heerspink, H. L., & Khunti, K. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100739 · Cited by 96
“Furthermore, sometimes there can be therapeutic complexities such that a medication for one disease can inadvertently worsen the control of another; for example, the use of pioglitazone [26] or saxagliptin [27,28] in the management of T2D has been associated with an increased risk of hospitalisation for HF.”
Background2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Salvo, F., Moore, N., Arnaud, M., Robinson, P., Raschi, E., De Ponti, F., Bégaud, B., & Pariente, A. (2016) · BMJ · doi:10.1136/bmj.i2231 · Cited by 99
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
“Although DPP-4is have proven cardiovascular safety [2, 3], only GLP-1RAs have demonstrated a reduction in major adverse cardiac events (MACE) [4, 5].”
Future glucose-lowering drugs for type 2 diabetes
Bailey, C. J., Tahrani, A. A., & Barnett, A. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00462-3 · Cited by 112
Lovshin, J. A., Rajasekeran, H., Lytvyn, Y., Lovblom, L. E., Khan, S., Alemu, R., Locke, A., Lai, V., He, H., Hittle, L., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0061 · Cited by 100
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
Sasso, F. C., Rinaldi, L., Lascar, N., Marrone, A., Pafundi, P. C., Adinolfi, L. E., & Marfella, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3106056 · Cited by 98
“Moreover, saxagliptin showed an increased rate of heart failure hospitalization [14].”
BackgroundPasternak, B., Ueda, P., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Wintzell, V., Melbye, M., et al. (2019) · BMJ · doi:10.1136/bmj.l4772 · Cited by 98
Hodkinson, A., Tsimpida, D., Kontopantelis, E., Rutter, M. K., Mamas, M. A., & Panagioti, M. (2022) · BMJ · doi:10.1136/bmj-2021-067731 · Cited by 107
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 121
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“Inhibition of DPP-4 by saxagliptin, alogliptin, or sitagliptin in the clinical trials SAVOR-TIMI 53 (Scirica et al., 2013), EXAMINE (alogliptin trial White et al., 2013) and TECOS (J. B. Green et al., 2015), respectively, did not increase the risk of CV death, MI or stroke in patients suffering…”
BackgroundMethodFudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99
Stromal derived factor 1α: A chemokine that delivers a two-pronged defence of the myocardium
Bromage, D. I., Davidson, S. M., & Yellon, D. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.009 · Cited by 97
“compared Saxagliptin and placebo in 16,492 patients with a history of, or at risk for, cardiovascular events (Scirica et al., 2013).”
BackgroundAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
Fisman, E. Z., & Tenenbaum, A. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0294-0 · Cited by 107
Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients
Rigato, M., Bittante, C., Albiero, M., Avogaro, A., & Fadini, G. P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1687 · Cited by 97
Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 98
“Notably, an increase in HF hospitalizations was observed with saxagliptin.(49) A phase III clinical trial of aleglitazar, a combined peroxisome proliferator-activated receptor-α/γ agonist (ALECARDIO), was halted due to”
BackgroundLong, M., Cai, L., Li, W., Zhang, L., Guo, S., Zhang, R., Zheng, Y., Liu, X., Wang, M., Zhou, X., et al. (2017) · Diabetes · doi:10.2337/db17-0934 · Cited by 105
Copeptin predicts coronary artery disease cardiovascular and total mortality
Tasevska, I., Enhörning, S., Persson, M., Nilsson, P. M., & Melander, O. (2015) · Heart · doi:10.1136/heartjnl-2015-308183 · Cited by 100
Statistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 103
Monami, M., Dicembrini, I., & Mannucci, E. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0892-7 · Cited by 99
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
Gourgari, E., Wilhelm, E. E., Hassanzadeh, H., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 95
Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults
Abusaib, M., Ahmed, M. J., Nwayyir, H. A., Alidrisi, H. A., Alabbood, M., Albayati, A. H., AL-Ibrahimi, S. M., Al-Kharasani, A. M. R., Alrubaye, H. F., Mahwi, T., et al. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420942232 · Cited by 123
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 104
Marfella, R., Sardu, C., Balestrieri, M. L., Siniscalchi, M., Minicucci, F., Signoriello, G., Calabrò, P., Mauro, C., Pieretti, G., Coppola, A., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0304-3 · Cited by 97
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodDiabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 101
Management of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
“The SAVOR, T ECOS and EXAMINE studies revealed that the incidence of pancreatic cancer did not dif fer between drug and placebo groups [92, 93].”
MethodThe perils of surrogate endpoints
Weintraub, W. S., Lüscher, T. F., & Pocock, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv164 · Cited by 112
Roumie, C. L., Min, J. Y., D'Agostino McGowan, L., Presley, C., Grijalva, C. G., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Elasy, T., & Griffin, M. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005379 · Cited by 95
“The associations reported between heart failure and thiazolidinediones or saxagliptin have been the subject of much debate, in part because these associations were identified as adverse event reports, not as prespecified outcomes in clinical trials that had other surrogate or cardiovascular events as outcomes.(7,8,39)…”
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 107
Bariatric surgery versus intensive medical therapy for diabetes.
Schauer, P. R., Bhatt, D. L., & Kashyap, S. (2014) · PubMed · doi:10.1056/nejmc1407393 · Cited by 35
Self-citationBohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32328-6 · Cited by 94
Self-citationPinto, L. C. F., Rados, D. R. V., Barkan, S. S., Leitão, C. B., & Gross, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-017-19055-6 · Cited by 96
Kohsaka, S., Lam, C. S. P., Kim, D. J., Cavender, M. A., Norhammar, A., Jørgensen, M. E., Birkeland, K. I., Holl, R. W., Franch‐Nadal, J., Tangri, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30130-3 · Cited by 104
Self-citationGlucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Barale, C., Buracco, S., Cavalot, F., Frascaroli, C., Guerrasio, A., & Russo, I. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0586 · Cited by 86
“• The bioactive native GLP-1(7-36)amide, the GLP-1 analogue Lir-”
BackgroundResultDiabetic cardiomyopathy: Pathophysiology, theories and evidence to date
Athithan, L., Gulsin, G. S., McCann, G. P., & Levelt, E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i10.490 · Cited by 102
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 105
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome
Harrington, J., Jones, W. S., Udell, J. A., Hannan, K. L., Bhatt, D. L., Anker, S. D., Petrie, M. C., Vedin, O., Butler, J., & Hernandez, A. F. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.02.008 · Cited by 106
Self-citationGilbert, R. E., & Thorpe, K. E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13754 · Cited by 92
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 95
Toh, S., Hampp, C., Reichman, M. E., Graham, D. J., Balakrishnan, S., Pucino, F., Hamilton, J., Lendle, S., Iyer, A., Rucker, M., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2568 · Cited by 91
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.